Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Ralph Edward Hoffman, Yale University
ClinicalTrials.gov Identifier:
NCT00042159
First received: July 24, 2002
Last updated: August 2, 2013
Last verified: August 2013
  Purpose

This study will evaluate the long-term effects of repetitive transcranial magnetic stimulation (rTMS) in patients with auditory hallucinations.


Condition Intervention
Schizophrenia
Hallucinations
Device: repetitive transcranial magnetic stimulation

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: TMS Intervention Development for Auditory Hallucinations

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Hallucination Change Score [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Total AHRS score [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
  • CGI [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
  • Frequency subscale of AHRS [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: July 2002
Study Completion Date: June 2004
Primary Completion Date: July 2003 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: repetitive transcranial magnetic stimulation
    1 Hertz stimulation for 16 minutes per day at 90% motor threshold, 5 sessions each to the two primary cortical targets
Detailed Description:

Auditory hallucinations can cause distress, functional disability, and problems in controlling behavior. In addition, auditory hallucinations are often resistant to drug treatment. Brain imaging studies suggest that voices arise from parts of the brain that are ordinarily involved in perceiving spoken speech. In TMS, an electromagnet placed on the scalp produces magnetic pulses that pass through the skull and stimulate the underlying cerebral cortex (a part of the brain). Low frequency (once per second) TMS is known to reduce reactivity or excitability of the part of the brain directly stimulated without damaging brain tissue. This study will determine if low frequency rTMS directed to brain areas responsible for speech processing can be used as an alternative treatment for auditory hallucinations and other related psychotic symptoms.

Before starting rTMS, patients will undergo: (1) a medical and psychiatric evaluation, (2) neuropsychological tests to assess concentration and memory abilities, and (3) an fMRI brain scan (which takes about 1 ¼ hours and does not require any injections). After these evaluations are completed, patients will be randomly assigned (e.g., by the flip of a coin) to receive either low frequency rTMS or placebo stimulation for 16 minutes per day over a 10-day period. During this time, the patient will not know whether (s)he is receiving the real or the placebo stimulation. For 5 days, stimulation will be administered to an area of the left temporal lobe of the brain that is involved in perceiving speech. This area is called Wernicke's area. For another 5-day period, a similar area on the right side of the brain will be stimulated. After the 10-day trial is completed, the patient will be told if (s)he received real or placebo TMS. If the patient received real TMS and experienced significant improvement in "voices", (s)he can choose to receive more stimulation to that part of the brain that produced greater improvement. If the patient has received only placebo stimulation, (s)he will then be offered a trial of real rTMS.

TMS is generally not painful, but can be uncomfortable due to a tingling or knocking sensation and/or contraction of scalp and facial muscles. There is a small risk of seizure associated with TMS, but for the frequency of stimulation used in this study (1 stimulation per second), this risk is significant only for patients who have a prior history of seizures, epilepsy, or other neurological problem. We have given TMS to more than 90 persons with schizophrenia and auditory hallucinations and have not had a case of seizure. We are also concerned that TMS may cause memory or concentration problems. Therefore, we carefully monitor patients for early signs of such difficulties, using daily questionnaire assessments and weekly neuropsychological tests. If we suspect that a patient is experiencing problems with memory or concentration, the trial is stopped. A small percentage of patients in our previous studies (less than 5%) reported problems with memory that ended soon after the trial was stopped.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have persistent auditory hallucinations

Exclusion Criteria:

  • History of neurological disorder
  • Serious, unstable medical conditions (persons with hypertension or diabetes mellitus may enroll if these conditions are treated and stable)
  • Active drug or alcohol abuse (persons may enroll if they have a history of drug or alcohol abuse provided that they do not use these substances at least 4 weeks prior to study initiation)
  • History of seizures unrelated to drug withdrawal
  • Estimated IQ less than 80
  • Have a sibling or parent with epilepsy
  • Disorganized thought process or intellectual impairment that inhibits the ability to give an informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00042159

Locations
United States, Connecticut
Yale-New Haven Psychiatric Hospital
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
  More Information

Additional Information:
Publications:
Responsible Party: Ralph Edward Hoffman, Principal Investigator, Yale University
ClinicalTrials.gov Identifier: NCT00042159     History of Changes
Other Study ID Numbers: R21 MH63326, R21MH063326, DSIR AT-SO
Study First Received: July 24, 2002
Last Updated: August 2, 2013
Health Authority: United States: Federal Government

Keywords provided by Yale University:
Auditory hallucinations (voices)

Additional relevant MeSH terms:
Hallucinations
Schizophrenia
Mental Disorders
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Perceptual Disorders
Schizophrenia and Disorders with Psychotic Features
Signs and Symptoms

ClinicalTrials.gov processed this record on November 25, 2014